Morgan Stanley Vertex Pharmaceuticals Inc Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Morgan Stanley holds 3,038,437 shares of VRTX stock, worth $1.24 Billion. This represents 0.1% of its overall portfolio holdings.

Number of Shares

3,038,437

Previous 3,258,628 6.76%

Holding current value

$1.24 Billion

Previous $1.53 Billion 7.48%

% of portfolio

0.1%

Previous 0.12%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$460.0 - $505.78 $101 Million - $111 Million	-220,191 Reduced 6.76%	3,038,437 $1.41 Billion
Q2 2024 Oct 17, 2024	BUY	$392.81 - $485.53 $29.1 Million - $36 Million	74,162 Added 2.33%	3,258,628 $1.53 Billion
Q2 2024 Aug 14, 2024	BUY	$392.81 - $485.53 $29.1 Million - $36 Million	74,162 Added 2.33%	3,258,628 $1.53 Billion
Q1 2024 Oct 17, 2024	SELL	$407.69 - $446.08 $30.2 Million - $33.1 Million	-74,162 Reduced 2.28%	3,184,466 $1.33 Billion
Q1 2024 Aug 16, 2024	BUY	$407.69 - $446.08 $83.2 Million - $91 Million	204,011 Added 6.84%	3,184,466 $1.33 Billion
Q1 2024 May 15, 2024	BUY	$407.69 - $446.08 $83.2 Million - $91 Million	204,011 Added 6.84%	3,184,466 $1.33 Billion
Q4 2023 Aug 16, 2024	SELL	$343.0 - $410.68 $95.4 Million - $114 Million	-278,173 Reduced 8.54%	2,980,455 $1.21 Billion
Q4 2023 Feb 13, 2024	BUY	$343.0 - $410.68 $37.9 Million - $45.3 Million	110,354 Added 3.84%	2,980,455 $1.21 Billion
Q3 2023 Nov 15, 2023	BUY	$338.18 - $362.46 $30.2 Million - $32.3 Million	89,217 Added 3.21%	2,870,101 $998 Million
Q2 2023 Aug 14, 2023	BUY	$314.42 - $351.91 $135 Million - $151 Million	427,823 Added 18.18%	2,780,884 $979 Million
Q1 2023 May 15, 2023	SELL	$283.23 - $323.1 $63.8 Million - $72.8 Million	-225,383 Reduced 8.74%	2,353,061 $741 Million
Q4 2022 Feb 14, 2023	BUY	$285.76 - $321.48 $183 Million - $206 Million	640,899 Added 33.08%	2,578,444 $745 Million
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $30.2 Million - $33.7 Million	110,320 Added 6.04%	1,937,545 $561 Million
Q2 2022 Oct 27, 2022	BUY	$234.96 - $292.55 $235 Million - $293 Million	1,001,376 Added 121.25%	1,827,225 $515 Million
Q2 2022 Aug 15, 2022	BUY	$234.96 - $292.55 $235 Million - $293 Million	1,001,376 Added 121.25%	1,827,225 $515 Million
Q1 2022 Oct 27, 2022	SELL	$221.42 - $260.97 $222 Million - $261 Million	-1,001,376 Reduced 54.8%	825,849 $216 Million
Q1 2022 May 13, 2022	SELL	$221.42 - $260.97 $31.9 Million - $37.6 Million	-143,958 Reduced 14.84%	825,849 $216 Million
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $12.9 Million - $16.2 Million	-72,706 Reduced 6.97%	969,807 $213 Million
Q3 2021 Nov 15, 2021	BUY	$181.39 - $202.99 $189 Million - $212 Million	1,042,513 New	1,042,513 $189 Million

Others Institutions Holding VRTX

# of Institutions

1,726

Shares Held

221M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $105B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account